{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:55:00Z","timestamp":1790902500740,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","award":["QoC019"],"award-info":[{"award-number":["QoC019"]}],"id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ero.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:54:29Z","timestamp":1761857669000},"page":"100043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-2621","authenticated-orcid":false,"given":"Stephanie R.","family":"Harrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Michelena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mac\u00eda-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0001","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0002","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2023.01.006","article-title":"Comorbidities in psoriatic arthritis: a narrative review","volume":"45","author":"Panagiotopoulos","year":"2023","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.ero.2025.07.007_bib0003","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3899\/jrheum.190054","article-title":"Psoriatic arthritis, psoriatic disease, or psoriatic syndrome?","volume":"46","author":"Lubrano","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.07.007_bib0004","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3899\/jrheum.190677","article-title":"Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis","volume":"47","author":"Zardin-Moraes","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.07.007_bib0006","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","article-title":"Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis","volume":"59","author":"Hag\u00e8ge","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0007","first-page":"159","article-title":"Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients\u2019 perception?","volume":"41","author":"Gialouri","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2025.07.007_bib0008","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","article-title":"Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study","volume":"76","author":"Michelsen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ero.2025.07.007_bib0009","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/rheumatology\/kez222","article-title":"Treatment failure in inflammatory arthritis: time to think about syndemics?","volume":"58","author":"Nikiphorou","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ero.2025.07.007_bib0010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11926-023-01097-7","article-title":"Have Therapeutics enhanced our knowledge of axial spondyloarthritis?","volume":"25","author":"Harrison","year":"2023","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103839","article-title":"Advances in precision medicine in imaging and therapeutic strategies for psoriatic disease","volume":"24","author":"Witte","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0013","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard-2023-225087","article-title":"Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey","volume":"83","author":"Marzo-Ortega","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2025.07.007_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ero.2025.07.007_bib0017","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ero.2025.07.007_bib0018","doi-asserted-by":"crossref","unstructured":"Harrison SR, Fragoulis GE, Mac\u00eda-Villa C, Michelena X, Falzon L, Machado PM, et al. Systematic review to inform the 2024 EULAR Task Force on Points to Consider for the Definition of Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA) [Internet]. International prospective register of systematic reviews (PROSPERO): National Institute of Health and Care Research; 2024 [cited 2025 Mar 31]. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=558589.","DOI":"10.1016\/j.ero.2025.07.007"},{"key":"10.1016\/j.ero.2025.07.007_bib0019","unstructured":"European Alliance for Rheumatology (EULAR). EULAR SOPs Standard Operating Procedures for Task Forces [Internet]. 2024 [cited 2025 Mar 31]. Available from: https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/996\/2a4b729e-cee6-4db8-99bf-aae42c61aa04\/909."},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0021","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"key":"10.1016\/j.ero.2025.07.007_bib0022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ero.2025.07.007_bib0023","series-title":"Newcastle-Ottawa Quality Assessment Scale [Internet]","author":"Wells","year":"2021"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0024","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s44158-023-00129-z","article-title":"Enhancing study quality assessment: an in-depth review of risk of bias tools for meta-analysis-a comprehensive guide for anesthesiologists","volume":"3","author":"De Cassai","year":"2023","journal-title":"J Anesth Analg Crit Care"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0025","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","article-title":"Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study","volume":"46","author":"Aaltonen","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0026","first-page":"41","article-title":"Potential difficult-to-treat psoriatic arthritis real-world prevalence and contributing factors","volume":"43","author":"Alp","year":"2025","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2025.07.007_bib0027","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s10067-020-05057-9","article-title":"Effectiveness of ustekinumab in patients with psoriatic arthritis in a real-world, multicenter study","volume":"39","author":"Azuaga","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0028","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0029","first-page":"176","article-title":"BioRePortAP, an electronic clinical record coupled with a database: an example of its use in a single centre","volume":"35","author":"Campanilho-Marques","year":"2010","journal-title":"Acta Reumatol Port"},{"issue":"5","key":"10.1016\/j.ero.2025.07.007_bib0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/ard.2007.082925","article-title":"Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience","volume":"67","author":"Coates","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.007_bib0031","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3389\/fphar.2019.01497","article-title":"Effectiveness of adalimumab for the treatment of psoriatic arthritis: an Italian real-life retrospective study","volume":"10","author":"D\u2019Angelo","year":"2019","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0032","first-page":"642","volume":"42","author":"Govoni","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0033","article-title":"Real-world effectiveness and persistence of golimumab as second-line anti-TNFalpha drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study","volume":"27","author":"D\u2019Angelo","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.007_bib0034","first-page":"75","article-title":"Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan [abstract]","author":"Erik","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.55563\/clinexprheumatol\/1sx5yk","article-title":"Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis","volume":"40","author":"Eviatar","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2025.07.007_bib0036","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0037","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/acr.23090","article-title":"Eight-year retention rate of first-line tumor necrosis factor inhibitors in spondyloarthritis: a multicenter retrospective analysis","volume":"69","author":"Favalli","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0038","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","article-title":"Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort","volume":"40","author":"Favalli","year":"2020","journal-title":"Rheumatol Int"},{"issue":"Suppl1","key":"10.1016\/j.ero.2025.07.007_bib0039","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/annrheumdis-2024-eular.5952","article-title":"AB0425\u2005Application of a prediction model to identify psoriatic arthritis patients with a higher difficultness-to-treat\u2014analysis from a single-centre cohort","volume":"83","author":"Ferrito","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4081\/reumatismo.2023.1544","article-title":"Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12\/23 drugs in a single-center cohort of psoriatic arthritis patients","volume":"75","author":"Ferrito","year":"2023","journal-title":"Reumatismo"},{"issue":"10","key":"10.1016\/j.ero.2025.07.007_bib0041","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3899\/jrheum.201204","article-title":"Treatment with tofacitinib in refractory psoriatic arthritis: a national multicenter study of the first 87 patients in clinical practice","volume":"48","author":"Galindez-Agirregoikoa","year":"2021","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0042","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-023-03182-9","article-title":"Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study","volume":"25","author":"Luchetti Gentiloni","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0043","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0044","first-page":"24","article-title":"Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients","volume":"43","author":"Gonzalez-Fernandez","year":"2019","journal-title":"Farm Hosp"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0045","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","article-title":"Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study","volume":"81","author":"Gossec","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0046","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-023-03058-y","article-title":"Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study","volume":"25","author":"Gossec","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0047","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ero.2025.07.007_bib0048","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2024-eular.876","article-title":"POS0958: clinical and ultrasound findings in difficult-to-treat PsA: results from the Leeds Specialist Spondyloarthritis Service [abstract]","volume":"83","author":"Harrison","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0049","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","article-title":"Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry","volume":"36","author":"Harrold","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","article-title":"Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis","volume":"47","author":"Iannone","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0051","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0052","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40261-019-00782-9","article-title":"Effectiveness of certolizumab-pegol in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis based on the BIOPURE registry: can early response predict late outcomes","volume":"39","author":"Iannone","year":"2019","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.07.011","article-title":"Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA","volume":"88","author":"Iannone","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0054","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3899\/jrheum.110763","article-title":"Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-alpha blockers","volume":"39","author":"Iervolino","year":"2012","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0055","first-page":"1106","article-title":"Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis","volume":"27","author":"Jin","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.ero.2025.07.007_bib0056","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1007\/s12325-023-02693-w","article-title":"Real-world persistence and treatment patterns in patients with psoriatic arthritis treated with anti-IL17 therapy in Spain: the PerfIL-17 study","volume":"40","author":"Joven","year":"2023","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0057","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from Southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0058","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/rheumatology\/keaa825","article-title":"Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis","volume":"60","author":"Lindstrom","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ero.2025.07.007_bib0059","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/annrheumdis-2024-eular.5569","article-title":"AB0424\u2005real-life experience of upadacitinib in psoriatic arthritis: results from a large, nationwide multicentric cohort","volume":"83","author":"Lopalco","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00296-015-3348-4","article-title":"Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany","volume":"36","author":"Lyu","year":"2016","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0061","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00296-021-04928-x","article-title":"Long-term survival of biological therapy in psoriatic arthritis: 18-year analysis of a cohort in a tertiary hospital","volume":"42","author":"Mateo Soria","year":"2022","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0062","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3109\/09546630902936752","article-title":"Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study","volume":"20","author":"Mazzotta","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ero.2025.07.007_bib0063","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/acr2.11556","article-title":"Real-world evidence assessing psoriatic arthritis by disease domain: an evaluation of the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"5","author":"Mease","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0064","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","article-title":"Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"10","author":"Mease","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40744-023-00631-4","article-title":"Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: results from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0066","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semarthrit.2019.07.003","article-title":"Four-year follow-up of inflammatory arthropathy patients treated with golimumab: data from the observational multicentre NOR-DMARD study","volume":"50","author":"Michelsen","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0067","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","article-title":"Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER Registry","volume":"9","author":"Moreno-Ramos","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"12","key":"10.1016\/j.ero.2025.07.007_bib0068","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/acr2.11347","article-title":"Real-world treatment patterns and healthcare costs in patients with psoriatic arthritis treated with ixekizumab: a retrospective study","volume":"3","author":"Murage","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0069","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/cer-2019-0023","article-title":"Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database","volume":"8","author":"Oelke","year":"2019","journal-title":"J Comp Eff Res"},{"issue":"Suppl 1","key":"10.1016\/j.ero.2025.07.007_bib0070","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/annrheumdis-2024-eular.4833","article-title":"AB0489 Real-life efficacy of risankizumab in psoriatic arthritis","volume":"83","author":"Pantano","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0071","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","article-title":"Clinical characteristics of potential \u2018difficult-to-treat\u2019 patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort","volume":"9","author":"Perrotta","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"10","key":"10.1016\/j.ero.2025.07.007_bib0072","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3899\/jrheum.2024-0101","article-title":"Difficult-to-treat concept in psoriatic arthritis: analysis of 2 potential definitions in a large group of patients. A Cross-Sectional Study","volume":"51","author":"Perrotta","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ero.2025.07.007_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152275","article-title":"Characteristics Of difficult-to-treat psoriatic arthritis: a comparative analysis","volume":"63","author":"Philippoteaux","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ero.2025.07.007_bib0074","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/rmdopen-2022-002681","article-title":"Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)","volume":"8","author":"Pina Vegas","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0076","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s42358-023-00296-1","article-title":"Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases","volume":"63","author":"Pombo-Suarez","year":"2023","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.ero.2025.07.007_bib0077","first-page":"75","article-title":"Do long-term patient-reported outcomes improve similarly in psoriatic arthritis and axial spondyloarthritis patients treated with secukinumab? Results from the EuroSpA Collaboration [abstract]","author":"Pons","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0078","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036245","article-title":"Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry","volume":"10","author":"Rahman","year":"2020","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0079","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/1744666X.2019.1631798","article-title":"Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations","volume":"15","author":"da Silva","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0080","doi-asserted-by":"crossref","first-page":"FSO369","DOI":"10.4155\/fsoa-2018-0101","article-title":"Medication persistence for psoriatic arthritis in a Brazilian real-world setting","volume":"5","author":"Ribeiro Da Silva","year":"2019","journal-title":"Future Sci OA"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0081","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-018-4324-7","volume":"38","author":"Rotar","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0082","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40744-024-00649-2","article-title":"The evaluation of effectiveness and safety of guselkumab in patients with psoriatic arthritis in a prospective multicentre \u2018real-life\u2019 cohort study","volume":"11","author":"Ruscitti","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0083","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0084","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/rheumatology\/kep423","article-title":"Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for","volume":"49","author":"Saad","year":"2010","journal-title":"Rheumatology Biologics Register. Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0085","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40744-021-00286-z","article-title":"Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis-a retrospective database study","volume":"8","author":"Sewerin","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0086","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jbspin.2014.08.001","article-title":"Treatment response, drug survival and safety of anti-tumour necrosis factor alpha therapy in 193 patients with psoriatic arthritis: a twelve-year \u2018real life\u2019 experience","volume":"82","author":"Soubrier","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0087","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ero.2025.07.007_bib0088","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/mr\/road111","article-title":"Long-term retention rates of anti-tumour necrosis factor and anti-interleukin-17 antibodies for patients with psoriatic arthritis","volume":"34","author":"Takami","year":"2024","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ero.2025.07.007_bib0089","first-page":"75","article-title":"AB2240: persistence to therapy among patients with psoriatic arthritis treated with IL-17A or TNF\u03b1 inhibitors (IL-17Ai or TNFi) [abstract]","author":"Vadhariya","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ero.2025.07.007_bib0090","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1093\/rheumatology\/keae263","article-title":"Identification and characteristics of patients with potential difficult-to-treat psoriatic arthritis: exploratory analyses of the Greek PsA registry","volume":"63","author":"Vassilakis","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ero.2025.07.007_bib0091","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3899\/jrheum.091477","article-title":"Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years","volume":"37","author":"Virkki","year":"2010","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.ero.2025.07.007_bib0092","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s12325-021-01687-w","article-title":"Treatment persistence and adherence among patients with psoriatic arthritis who initiated targeted immune modulators in the US: a retrospective cohort study","volume":"38","author":"Walsh","year":"2021","journal-title":"Adv Ther"},{"issue":"7","key":"10.1016\/j.ero.2025.07.007_bib0093","first-page":"623","article-title":"Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database","volume":"24","author":"Walsh","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.ero.2025.07.007_bib0094","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/14737167.2020.1800456","article-title":"Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting","volume":"20","author":"Zagni","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13075-014-0420-5","article-title":"Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs","volume":"16","author":"Zhang","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"Suppl1","key":"10.1016\/j.ero.2025.07.007_bib0096","first-page":"1761","article-title":"AB1082: early clinical response as a predictor of long-term health-related quality of life improvements in patients with psoriatic arthritis and TNFI-IR receiving guselkumab (COSMOS)","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0097","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002706","article-title":"AB1415: importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis [abstract]","volume":"8","author":"Snoeck Henkemans","year":"2022","journal-title":"RMD Open"},{"issue":"suppl 9","key":"10.1016\/j.ero.2025.07.007_bib0098","article-title":"Bimekizumab treatment impact on work productivity in biologic DMARD\u2011na\u00efve and TNFi-IR patients with active psoriatic arthritis: results up to 1 year from two phase 3 studies [abstract]","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2025.07.007_bib0099","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1007\/s12325-023-02600-3","article-title":"Identifying predictors of first-line subcutaneous TNF-inhibitor persistence in patients with inflammatory arthritis: a decision tree analysis by indication","volume":"40","author":"Dalen","year":"2023","journal-title":"Adv Ther"},{"issue":"9","key":"10.1016\/j.ero.2025.07.007_bib0100","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s10067-022-06230-y","article-title":"Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA","volume":"41","author":"Hunter","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ero.2025.07.007_bib0101","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1007\/s10067-021-05799-0","article-title":"Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFalpha, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study","volume":"40","author":"Lorenzin","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.ero.2025.07.007_bib0102","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/acr.25112","article-title":"Persistence of biologics in the treatment of psoriatic arthritis: data from a large hospital-based longitudinal cohort","volume":"75","author":"Rida","year":"2023","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/03009742.2023.2258644","article-title":"Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?","volume":"53","author":"Roseman","year":"2024","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0104","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/rheumatology\/keae149","article-title":"Characteristics associated with patient-reported treatment success in psoriatic arthritis","volume":"64","author":"Samuel","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ero.2025.07.007_bib0105","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3899\/jrheum.181272","article-title":"Real-world longterm effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the Rheumatic Diseases Portuguese Register","volume":"47","author":"Vieira-Sousa","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/1346-8138.14745","article-title":"Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-alpha inhibitors","volume":"46","author":"Tsuruta","year":"2019","journal-title":"J Dermatol"},{"issue":"Suppl1","key":"10.1016\/j.ero.2025.07.007_bib0107","article-title":"POS1551: drug switching due to inefficacy in psoriatic arthritis patients treated with biological agents. Daily clinical experience [abstract]","volume":"82","author":"Rodr\u00edguez Laguna","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"Suppl1","key":"10.1016\/j.ero.2025.07.007_bib0108","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2023-eular.3948","article-title":"AB1138: Difficult-to-treat psoriatic arthritis: analysis of a single-centre cohort from northern Italy [abstract]","volume":"82","author":"Cincinelli","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.007_bib0109","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/annrheumdis-2024-eular.5297","article-title":"AB0467 predictive factors of the first bdmard switch in psoriatic arthritis patients [abstract]","volume":"83","author":"Ferreira","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ero.2025.07.007_bib0110","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2024-eular.3430","article-title":"AB0397\u2005characteristics of patients with difficult to treat psoriatic arthritis: results from e.pulse, the nationwide health data [abstract]","volume":"83","author":"Kalyoncu","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ero.2025.07.007_bib0111","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.ero.2025.07.007_bib0112","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","article-title":"Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis","volume":"5","author":"Eder","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.ero.2025.07.007_bib0113","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic-\/targeted synthetic-DMARDs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. A systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0114","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1759720X18783894","article-title":"Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review","volume":"10","author":"Nikiphorou","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ero.2025.07.007_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.02.013","article-title":"Obesity substantially impacts rheumatic and musculoskeletal diseases: time to act","author":"Sattar","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.007_bib0116","article-title":"Weighing in on obesity and psoriatic arthritis\u2013time to move beyond association to robust randomised trials","author":"Siebert","year":"2025","journal-title":"Joint Bone Spine"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0117","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/ard.2009.107912","article-title":"Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study","volume":"69","author":"Cavanagh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2025.07.007_bib0118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbi.2015.08.005","article-title":"Circulating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans","volume":"51","author":"Krishnadas","year":"2016","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ero.2025.07.007_bib0119","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbi.2024.08.048","article-title":"The inflammatory underpinning of depression: an historical perspective","volume":"122","author":"Yirmiya","year":"2024","journal-title":"Brain Behav Immun"},{"issue":"8","key":"10.1016\/j.ero.2025.07.007_bib0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0121","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0122","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ero.2025.07.007_bib0123","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","article-title":"The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs","volume":"61","author":"Tucker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0124","article-title":"Recent advances in the management of psoriatic arthritis: practical considerations","volume":"134","author":"Harrison","year":"2024","journal-title":"Pol Arch Intern Med"},{"issue":"4","key":"10.1016\/j.ero.2025.07.007_bib0125","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004176","article-title":"Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature","volume":"10","author":"Grohmann","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ero.2025.07.007_bib0126","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054539","article-title":"Biomarkers in psoriatic arthritis: a meta-analysis and systematic review","volume":"13","author":"Wirth","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ero.2025.07.007_bib0127","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/CMR.17.2.348-369.2004","article-title":"HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations","volume":"17","author":"Colmegna","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ero.2025.07.007_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.614255","article-title":"Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis","volume":"12","author":"McGonagle","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.12840","article-title":"Interleukin-23 pathway at the enthesis: the emerging story of enthesitis in spondyloarthropathy","volume":"294","author":"Bridgewood","year":"2020","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.ero.2025.07.007_bib0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","article-title":"Psoriatic arthritis in males and females: differences and similarities","volume":"10","author":"Lubrano","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.ero.2025.07.007_bib0131","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jid.2023.11.010","article-title":"Age at natural menopause, reproductive lifespan, and the risk of late-onset psoriasis and psoriatic arthritis in women: a prospective cohort study","volume":"144","author":"Xiao","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.ero.2025.07.007_bib0132","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.ero.2025.07.007_bib0133","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/art.43105","article-title":"Immune aging in rheumatoid arthritis","volume":"77","author":"Weyand","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ero.2025.07.007_bib0134","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.05133.x","article-title":"Th1 and Th17 cells: adversaries and collaborators","volume":"1183","author":"Damsker","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"10.1016\/j.ero.2025.07.007_bib0135","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/1744666X.2021.1970534","article-title":"Ixekizumab: an IL-17A inhibitor for the treatment of axial spondylarthritis","volume":"17","author":"Harrison","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"21","key":"10.1016\/j.ero.2025.07.007_bib0136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/ijms21217873","article-title":"Paradoxical psoriasis induced by anti-TNF\u03b1 treatment: evaluation of disease-specific clinical and genetic markers","volume":"21","author":"Bucalo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ero.2025.07.007_bib0137","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:20:19Z","timestamp":1790900419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050708125000618"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.07.007","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence, outcomes, and predictive factors: a systematic literature review to inform the development of EULAR Points to Consider for the definition of Difficult-to-Manage and Treatment-Refractory psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.10.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100043"}}